| |
No infliximab serum trough level
|
Low* infliximab trough levels
|
Intermediate infliximab trough levels
|
High** infliximab trough levels
|
Anti-infliximab antibodies
|
Total
|
|---|
|
DAS28
|
% (95%CI)
|
% (95%CI)
|
% (95%CI)
|
% (95%CI)
|
% (95%CI)
|
No patients
|
|
<2.6
|
13 (2–23)
|
23 (10–35)
|
48 (32–63)
|
18 (6–29)
|
13 (2–23)
|
40
|
|
≤3.2
|
13 (4–20)
|
18 (9–28)
|
55 (43–67)
|
14 (5–22)
|
11 (3–19)
|
65
|
|
>3.2
|
29 (19–39)
|
18 (10–27)
|
32 (22–42)
|
21 (12–30)
|
29 (19–39)
|
82
|
- * Low serum trough levels are defined as <1.0 mg/L.
- ** High serum trough levels are defined as >5.0 mg/L.
